Evaluation of a synthetic peptide-based assay and a rapid dot-blot recombinant test for detection of antibodies to HIV-1 and HIV-2. NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Evaluation of a synthetic peptide-based assay and a rapid dot-blot recombinant test for detection of antibodies to HIV-1 and HIV-2.

J Egypt Public Health Assoc. 1990;65(1-2):1-10. Unique Identifier : AIDSLINE MED/92166669
Constantine NT; Farag MM; Watts DM; Division of Virology, U.S. Naval Medical Research Unit No. 3,; Cairo, Egypt.

Abstract: Our objective was to evaluate two new serologic assays for detecting HIV-1 and HIV-2 positive and negative sera. A total of 154 human sera from African countries were tested using a synthetic peptide-based passive hemagglutination assay (PHA) and a rapid dot-blot recombinant test (Test-Pack), both of which are marketed as HIV-1/HIV-2 combination assays. Results indicated that the PHA identified all HIV-1 and HIV-2 positive sera, although some were only weakly reactive. It produced one false positive reaction. The Test-Pack correctly detected all positive and negative sera, although several negative sera produced extremely weak reactions. Both tests detected two HIV-2 positive sera which were non-reactive by HIV-1 screening assays.
Keywords: Comparative Study Evaluation Studies False Negative Reactions False Positive Reactions *Hemagglutination Tests Human HIV Antibodies/*ISOLATION & PURIF *Immunoblotting Predictive Value of Tests Sensitivity and Specificity Support, U.S. Gov't, Non-P.H.S. JOURNAL ARTICLEKWDcomparativestudyevaluationstudiesfalsenegativereactionsfalsepositivereactionsKWDhemagglutinationtestshumanhivantibodies/KWDisolation&purifKWDimmunoblottingpredictivevalueoftestssensitivityandspecificitysupport,uKWDsKWDgov't,non-pKWDhKWDsKWDjournalarticle
920630
M9260998

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .